Home > Resources > Whitepapers > Better ways to handle tablets using IBCs

Better ways to handle tablets using IBCs

May 30, 2019

It is common to find Intermediate Bulk Containers (IBCs) being used for handling powders and granules in solid dosage manufacturing processes, from initial Dispensing through to Tablet Compression or Capsule Filling. The benefits of using IBCs for efficient and flexible materials handling at this stage of the process are widely appreciated and applied in modern facilities. However, when it comes to tablets, these are still traditionally handled in small containers such as drums, small kegs or boxes. In this article Shaun Baker, Pharmaceutical Sales Director for Matcon Limited, considers the benefits and challenges of handling tablets in larger volumes and using IBCs.

I'm For Real

Enter your details once to access all our information and resources

Spotlight

Fresenius Group

Fresenius is a globally active health care group providing products and services for dialysis, hospitals and the medical care of patients at home. In addition, Fresenius focuses on clinic operations as well as on engineering and services for hospitals and other health care facilities.

OTHER WHITEPAPERS
news image

Asia Pacific as a Clinical Trials Powerhouse

whitePaper | October 6, 2022

Patient availability is a critical component for clinical trials, and so it stands to reason that clinical development should match the epidemiology of diseases. Of course, this is often not the case,

Read More
news image

A Comparison of Substance Use Disorders before and during theCOVID-19 Pandemic

whitePaper | September 22, 2022

During the COVID-19 pandemic, drug overdose deaths have increased. At the same time, access to and utilization of substance use disorder treatment services have decreased.

Read More
news image

Essential for Stable U.S. Supply Chains of Quality Pharmaceuticals

whitePaper | May 11, 2022

CDER is taking another step towards realizing the vision for pharmaceutical quality in the 21st century: a maximally efficient, agile, flexible manufacturing sector that reliably produces high-quality drug products without extensive regulatory oversight.

Read More
news image

Starting Materials For Homeopathic Drug Products

whitePaper | December 31, 2021

The scope of this white paper includes GMPs relevant for mass manufacturing/batch53 processing of products intended for widescale retail marketing. Starting materials and 54 packaging components for drug products

Read More
news image

A Brief Synopsis of Modern Randomization Methodologies and Technologies

whitePaper | December 9, 2022

Randomized, double-blind clinical trials are the gold standard for adequate and well-controlled studies in modern times. However, prior to the late 1940s, randomization and blinding were not used in medicine and as result, bias was common.

Read More
news image

Optimizing the Path from Pre-Clinical to Clinical Development

whitePaper | December 22, 2022

According to research, post-pandemic R&D growth is healthy in the pharma industry with the number of drugs in the R&D pipeline now exceeding 20,000 in 2022—which represents an expansion rate of 8.22% from 2021 (1).

Read More

Asia Pacific as a Clinical Trials Powerhouse

whitePaper | October 6, 2022

Patient availability is a critical component for clinical trials, and so it stands to reason that clinical development should match the epidemiology of diseases. Of course, this is often not the case,

Read More

A Comparison of Substance Use Disorders before and during theCOVID-19 Pandemic

whitePaper | September 22, 2022

During the COVID-19 pandemic, drug overdose deaths have increased. At the same time, access to and utilization of substance use disorder treatment services have decreased.

Read More

Essential for Stable U.S. Supply Chains of Quality Pharmaceuticals

whitePaper | May 11, 2022

CDER is taking another step towards realizing the vision for pharmaceutical quality in the 21st century: a maximally efficient, agile, flexible manufacturing sector that reliably produces high-quality drug products without extensive regulatory oversight.

Read More

Starting Materials For Homeopathic Drug Products

whitePaper | December 31, 2021

The scope of this white paper includes GMPs relevant for mass manufacturing/batch53 processing of products intended for widescale retail marketing. Starting materials and 54 packaging components for drug products

Read More

A Brief Synopsis of Modern Randomization Methodologies and Technologies

whitePaper | December 9, 2022

Randomized, double-blind clinical trials are the gold standard for adequate and well-controlled studies in modern
times. However, prior to the late 1940s, randomization and blinding were not used in medicine and as result,
bias was common.

Read More

Optimizing the Path from Pre-Clinical to Clinical Development

whitePaper | December 22, 2022

According to research, post-pandemic R&D growth is healthy in the pharma industry with the number of drugs in the R&D pipeline now exceeding 20,000 in 2022—which represents an expansion rate of 8.22% from 2021 (1).

Read More
More Whitepapers

Spotlight

Fresenius Group

Fresenius is a globally active health care group providing products and services for dialysis, hospitals and the medical care of patients at home. In addition, Fresenius focuses on clinic operations as well as on engineering and services for hospitals and other health care facilities.

Events